Newly Approved Medication Update
Golden L. Peters, Pharm.D., BCPS

In 2019, 48 new medications were approved by the FDA and so far in 2020 there have been 6 newly approved medications. The presentation will highlight selected new medications to review each medications indication, specific mechanism of action, dosing information, contraindications, precautions, adverse drug reactions, drug interactions, special administration techniques (when needed), and potential place in current therapy. The presentation will also highlight any special patient instruction or monitoring parameters for providers to take into account when prescribing these new medications. (e.g. injection techniques, priming requirements) New generic medications will be presented, along with any updated FDA recommendations or recent labeling changes to mainstream medications.

The Highs & Lows of Antihypertensive Therapy
Dr. Richard Ihnat

We will review guideline-driven antihypertensive therapy and what to do with more complex patients who fail to respond to initial, multidrug therapy.

Primary Care Management of Anxiety and Depression Medication.
Debbie Lynn Kelly, MSN, RN, PMHNP-BC

This interactive session will discuss medication management of anxiety and depression in primary care. The discussion will include a brief review of the prevalence of both depression and anxiety, screening tools that can be used when prescribing and when to refer to psychiatry as well as small group discussion/case studies.
Update on Pharmacotherapy for Obesity
Susan R. Reeds, MD, FACP

Discuss indications/rationale for use of medications in the treatment of obesity. Review currently available anti-obesity medications and their appropriate use. This will include mechanism of action of medications, choice of medication in specific circumstances, discussion of off-label use of medications not FDA-approved for treating obesity.

Diabetes Management
Dr Jerry Thurman

This session will focus on the new ADA guidelines with emphasis on heart disease. We will take an in depth look at GLP and SGLT mechanisms of action and potential benefits with patients with Type 2 diabetes. These two classes of drugs now rank higher on the guidelines especially in persons with CAD and DM.